IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Thomas Nissl Confirmation No. 7923

Application No. 10/573,948

Filed: May 1, 2007

For: **REMOVABLE STENT**

Group Art Unit: 3738

Examiner: Tiffany P. Shipmon

Attorney Docket No. 37621/51901

Date: February 8, 2011

INFORMATION DISCLOSURE STATEMENT

TO TI	HE CO	MMISSIONER FOR PATENTS:				
1.		Pursuant to the duty of disclosure, documents listed on the accompanying Form PTO-1449 (or equivalent) are presented for the Examiner's consideration.				
		Copies of listed U.S. patents and U.S. patent application publications are not required for submission. (37 C.F.R. § 1.98(a)(2)(ii))				
		Copies of listed foreign patent documents and/or non-patent literature are enclosed. (37 C.F.R. § 1.98(a)(2))				
		Copies of the documents listed at (sheet/cite no.) of the attached Form PTO-1449 (or equivalent) are omitted because (1) they are already of record in U.S. Patent Application No, filed, on which this application relies for an earlier filing date under 35 U.S.C. § 120; and (2) any information disclosure statement filed in the prosecution of Application No, complies with 37 CFR §§ 1.98(a) through (c). (37 C.F.R. § 1.98(d))				
		A copy of copending U.S. Patent Application No, filed, for, listed at (sheet/cite no.) of the attached Form PTO-1449 (or equivalent), is enclosed / is omitted. (Copy not required if available via IFW. 1287 OG 162 (Oct. 19, 2004).).				
2.	This information disclosure statement is being submitted (check box a., b., or c.):					
	a.	Within three months of the filing date of a national application or entry of the national stage in an international application; or before the mailing of a first Office action on the merits; or before the mailing of a first Office				

			action after the filing of a request for continued examination under 37 CFR 1.114. (No statement under 37 CFR 1.97(e) is required.); or			
	b.		After the period set forth in paragraph 2a, but before the mailing date of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or ii.)			
		i.		The \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is paid herewith, or		
		ii.		A statement specified by 37 CFR 1.97(e) is set forth below; or		
	c.		before is set for	ne mailing date of a final action or notice of allowance and on or payment of the issue fee. A statement specified by 37 CFR 1.97(e) orth below. Enclosed is the \$180.00 information disclosure ent processing fee set forth in 37 CFR 1.17(p).		
3.	Fee Payment					
	a.		A chec	k in the amount of \$ is enclosed.		
	b.	\boxtimes	Paymen	nt by credit card.		
	c.		_	charge our Deposit Account No. 502375 in the amount of		
	d.		which 1	immissioner is hereby authorized to charge any additional fees may be required in connection with filing of these papers, or credit yment to Deposit Account No. 502375.		
1.			specifies states th	d by 37 CFR 1.97(e) is required, the attorney or agent signing at:		
		formation contained in this information disclosure statement was ay communication from a foreign patent office in a counterpart ation not more than three months prior to the filing of the sclosure statement; or				
		no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement				

2

70542466.1 0037621-51901

5.	A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is set forth below.				
	Respectfully submitted,				
	Merit Medical Systems, Inc.				
	By /Matthew S. Bethards/				
	36.4				

Matthew S. Bethards Registration No. 51,466

STOEL RIVES LLP One Utah Center Suite 1100 201 S Main Street Salt Lake City, UT 84111-4904 Telephone: (801) 328-3131 Facsimile: (801) 578-6999